OCC — Orthocell Income Statement
0.000.00%
- AU$272.55m
- AU$244.50m
- AU$9.23m
- 28
- 16
- 64
- 27
Annual income statement for Orthocell, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.22 | 1.62 | 5.09 | 6.76 | 9.23 |
Cost of Revenue | |||||
Gross Profit | 0.592 | 0.913 | 4.07 | 5.14 | 6.48 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.6 | 12.9 | 14.5 | 17 | 21 |
Operating Profit | -11.4 | -11.3 | -9.41 | -10.2 | -11.8 |
Net Income Before Taxes | -11.4 | -11.3 | -9.41 | -10.2 | -11.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.04 | -9.11 | -6.25 | -7.18 | -8.57 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.04 | -9.11 | -6.25 | -7.18 | -8.57 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.04 | -9.11 | -6.25 | -7.18 | -8.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.049 | -0.047 | -0.032 | -0.035 | -0.038 |